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Abstract
Background: The function of the 19 kDa C-terminal region of the merozoite surface protein 1 (MSP1-19) expressed by
Plasmodium has been demonstrated to be conserved across distantly related Plasmodium species. The green fluorescent
protein (GFP) is a reporter protein that has been widely used because it can be easily detected in living organisms by
fluorescence microscopy and flow cytometry.
Methodology and Results: In this study, we used gene targeting to generate transgenic P. berghei (Pb) parasites
(designated as PfMSP1-19Pb) that express the MSP1-19 of P. falciparum (Pf) and the GFP reporter protein simultaneously.
The replacement of the PbMSP1-19 locus by PfMSP1-19 was verified by PCR and Southern analysis. The expression of the
chimeric PbfMSP-1 and the GFP was verified by Western blot and fluorescence microscopy, respectively. Moreover, GFP-
expressing transgenic parasites in blood stages can be readily differentiated from other blood cells using flow cytometry. A
comparion of growth rates between wild-type and the PfMSP1-19Pb transgenic parasite indicated that the replacement of
the MSP1-19 region and the expression of the GFP protein were not deleterious to the transgenic parasites. We used this
transgenic mouse parasite as a murine model to evaluate the protective efficacy in vivo of specific IgG elicited by a PfCP-2.9
malaria vaccine that contains the PfMSP1-19. The BALB/c mice passively transferred with purified rabbit IgG to the PfCP-2.9
survived a lethal challenge of the PfMSP1-19Pb transgenic murine parasites, but not the wild-type P. berghei whereas the
control mice passively transferred with purified IgG obtained from adjuvant only-immunized rabbits were vulnerable to
both transgenic and wild-type infections.
Conclusions: We generated a transgenic P. berghei line that expresses PfMSP1-19 and the GFP reporter gene
simultaneously. The availability of this parasite line provides a murine model to evaluate the protective efficacy in vivo
of anti-MSP1-19 antibodies, including, potentially, those elicited by the PfCP-2.9 malaria vaccine in human volunteers.
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Introduction
There is an urgent need for the development of a malaria
vaccine to control the tropical disease because of the emergence
and rapid spread of drug-resistant parasites and insecticide-
resistant mosquitoes [1]. The 185–215 kDa merozoite surface
protein 1 of Plasmodium falciparum (PfMSP1) is a leading anti-blood
stage malaria vaccine candidate [2,3]. The PfMSP1 undergoes
proteolytic processing during merozoite maturation resulting in
four major fragments of 83, 30, 38 and 42 kDa [4]. Before
erythrocyte invasion, the 42-kDa fragment undergoes a secondary
proteolytic cleavage, leaving the C-terminal 19-kDa fragment
(MSP1-19) associated with merozoites in newly invaded erythro-
cytes [5]. Antibodies that are specific for MSP1-19 comprise a
large component of the inhibitory activities observed in naturally
exposed individuals [6,7]. Several vaccination studies using MSP1-
19 in both mice and monkeys have shown partial protection
against parasite challenge [8,9]. In addition to PfMSP1, the apical
membrane antigen of Plasmodium falciparum (PfAMA-1) is another
attractive vaccine candidate against blood-stage parasite [2,10–
12]. The most C-terminal of the disulphide-bonded domains in
AMA-1 (AMA-1(III)) was demonstrated to be the target of
inhibitory antibodies isolated from humans in malaria-endemic
regions [13].We have constructed a Plasmodium falciparum chimeric
protein that consists of AMA-1(III) and MSP1-19 (designated as
PfCP-2.9) [14,15]. The sera from vaccinated rabbits and rhesus
monkeys with PfCP-2.9 formulated by Montanide ISA 720 almost
completely inhibited in vitro growth of P. falciparum FCC1/HN and
3D7 lines. The PfCP-2.9 vaccine candidate is being tested in
clinical trials [16,17].
Malaria vaccine development requires appropriate experimen-
tal animal models for the evaluation of the efficacy of a vaccine in
vivo. Although trials in Aotus monkeys have provided important
information on the protective efficacy of malaria vaccine
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Although growth inhibition assays could provide information
about the inhibitory function of antibodies, these provide only in
vitro assessment and do not represent the true efficacy of immune
sera in vivo [19,20]. Therefore, alternative models for the in vivo
evaluation of vaccine efficacy are urgently needed.
It was recently reported that transgenic murine malaria parasites
that express human malaria genes were generated for the
assessment of vaccine-inducing antibodies [21–23]. Although the
role of the PfMSP1 gene is essential for development of the blood
stage of the parasite, allelic replacement experiments have shown
that the function of the MSP1-19 fragment is highly conserved
across distantly related Plasmodium species [24]. The green
fluorescent protein (GFP) is a well-established reporter protein that
has been exploited in a large variety of cell-type analysis systems
[25]. Stable episomal or integrated expression of GFP has been
reported in Plasmodium for the examination of gene expression,
protein localization and biological processes [26,27]. In this study,
we utilized gene targeting to develop transgenic P. berghei parasites
that expressed P. falciparum MSP1-19 as well as GFP. This
transgenic parasite line can be readily detected in all blood stages
using fluorescent microscope and flow cytometry. The growth
characteristics of the fluorescent transgenic parasites in the blood
stage were similar to wild type P. berghei. We employed transgenic
rodent parasites as an in vivo murine model to further assess the
protective efficacy of anti-MSP1-19 antibodies elicited by PfCP-2.9.
Materials and Methods
Parasites and experimental animals
The ANKA strain of P. berghei used in this study is an uncloned
line that was obtained from the National Institute for Parasitic
Diseases of the Chinese Center for Disease Control and
Prevention. The P. berghei ANKA parasites were maintained by
mechanical passage in mice.
Inbred BALB/c mice, outbred KM mice and New Zealand
White rabbits were purchased from the Shanghai Laboratory
Animal Center of the Chinese Academy of Sciences. All of the
mice were housed in specific pathogen free (SPF) standards while
the rabbits were housed in a conventional animal facility. All of the
procedures performed on animals within this study were
conducted in accordance with the guidelines of the Committee
on Animals of the Second Military Medical University.
Plasmid construction
The P. berghei transfection vector pPyrFlu which contains the GFP
gene, was generously provided by Dr. Robert Me ´nard (Institut
Pasteur, Paris, France) [28]. To create the PbfMSP1 fusion gene, the
1,423-base pair (bp) P. berghei MSP1 targeting sequence and the 330-
bp PfMSP1-19 fragment were PCR amplified from a P. falciparum
FCC1/HN isolate and P. berghei ANKA genomic DNA, respectively,
using primers PbF (59-CGCGAGCTCTTAACAAAAGAAGA-
GAAGC-39) and PbR (59-GCATACATGCTTAGGGTCTA-
TACCTAATAAATC-39), and PfF (59-GGTATAGACCCTAAG-
CATGTATGCGTAAAAAAACAATGTCCAG-39) and PfR
(59-CGCGTCGACTTAAATGAAACTGTATAATATTAAC-39).
The two PCR products were fused in frame by using the primers PbF
a n dP f Ra n dr e s u l t e di nP b f M S P 1 .T h e8 6 0 - b pP f H S P 8 63 9
untranslated region (UTR) was amplified from plasmid pHC1 (a gift
from the Malaria Research and Reference Reagent Resource Center)
using the primers HSPF (59-CGGCTCGAGTTATATAATA-
TATTTATGTAC-39) and HSPR (59-CGGGGATCCTATTT-
GATGAATTAACTACAC-39) and ligated in the correct orientation
to PbfMSP1 to create a 2.6 kb fragment that was cloned into the
SacI/BamHI sites of pPyrFlu. The other 0.5 kb targeting sequence of
PbMSP-1 39UTR was also amplified from P. berghei ANKA genomic
DNA using the primers Pb39F( 5 9-GGCGGGCCCATAAAT-
TATTGAAATATTTGTTG-39) and Pb39R( 5 9-CGCGGTACC-
TATACAAAACATATACA-39) and then cloned into the ApaI/KpnI
sites of pPyrFlu. The resulting vector containing PyrFlu/PbfMSP-1/
PbM39 was linearized with KpnIa n dSacI before transfection.
Transfection, cloning and genotype analysis of
transgenic parasites
Transfection of the blood stages of the P. berghei ANKA strain and
the selection of transfected parasites was performed as described
previously [29]. Individual clones were obtained by injecting 1
infected erythrocyte per mouse intravenously. Briefly, the blood
cells were collected from an infected mouse and diluted with
complete medium to generate the cell suspension. Then, we
determined the erythrocyte density of the cell suspension using a
blood cell-counter. The number of infected cells in the suspension
was calculated by the erythrocyte density and the parasitemia
determined on Giemsa-stained blood smears. The cell suspension
was further diluted with complete culture medium to 1 infected
RBC per 100 ml. Thus, 100 ml of this suspension was injected into
mice through the tail vein. For analysis of the genotype of post-
transfection parasite clones, genomic DNA was isolated from the
blood of asynchronous infected mice using a TIANamp Blood
Genomic DNA Kit (Tiangen Biotech, Beijing, China) and analyzed
by PCR and Southern blot. The correct integration was determined
by PCR using the test primers as described below. The presence of
the GFP reporter gene was confirmed by PCR using the primers
gfpF( 5 9-ATGAGTAAAGGAGAAGAACTTTTC-39)a n dgfpR( 5 9-
TTATTTGTATAG TTCATCCATGC-39). The presence of the
transfection vector in respective clones was detected by PCR using
the primers Tb (59 –CATCGACACCAGAAGAAGTAGCAAG-
39) and Tf (59-CCGTTGCTACCTGAATCTTCTTCG-39),
which amplified PbfMSP1 fused from 1.4 kb of the P. berghei
MSP1 targeting sequence and 330 bp of the PfMSP1-19 fragment.
To verify the 59 integration fidelity at the P. berghei MSP1 gene, the
primers Tb5 (59-GAAATCGCACACTTAAAGGAATTATCA-
GAG-39), specific for a sequence upstream of the 1.4 Kb P. berghei
MSP1 targeting sequence, and Tf were used. As a control, the
primers Tb5 and T-Pb (59-GAATTTTCCCTATTTTCCG-
CAGTT-39), specific to P. berghei MSP1-19, were used in the PCR
to identify the wild-type parasites. To verify the 39 integration
fidelity, the primer 39veF (59 –TACACAAACATACAAAAA-
TAAAC-39), specific to P. berghei DT 59UTR, and the primer
39veR (59 –ATAATACAACAAAATGGATA-39), specific to a
sequence downstream of the P. berghei MSP1 39UTR targeting
sequence, were used. Schematic representations of all of the primers
are shown figures 1A, B and C.
We also performed a Southern blot experiment to further confirm
the integration using a 430-bp probe prepared by PCR amplification
of the fragment derived from the transfection vector PyrFlu/
PbfMSP-1/PbM39 using the primers PbMF (59-TAAAA-
TATGCTGCTAAAG-39) and PbMR (59-GATTCGCCTTCTCC-
TACC-39). Individual HincII-digested genomic DNA fragments of
wild-type and transgenic P. berghei parasites were hybridized to the
probe by standard procedures [30] following the manufacturer’s
instructions of the North2SouthH direct HRP labeling and detection
kit (Pierce, Rockford, IL, USA). Schematic representations of the
probe and digestion fragments are shown the figures 1C.
In order to test the passage stability, 10
6transgenic P. berghei parasites
were inoculated intraperitoneally (i.p.) into 5 naı ¨ve KM mice without
pyrimethamine pressure. Each week, 50 ml of blood taken from
infected mice was diluted in 500 ml PBS and passaged into 5 new KM
Transgenic Pb Parasite
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e6894mice. This was repeated 5 times. The infected blood collected from
each passage was used for the extraction of genomic DNA. Ten
micrograms of genomic DNA was digested by HincII overnight and
subjected to Southern analysis according to the above-mentioned
protocol. The genomic DNA from wild type P. berghei w a su s e da sa
control.
Figure 1. Generation of mutant P. berghei parasites and PCR analysis. Organizational maps of plasmid PyrFlu (A), the construction strategy of
recombinant vector PyrFlu/PbfMSP-1/ PbM39 (B), the gene map following the homologous integration of plasmid PyrFlu/PbfMSP-1/ PbM39 at the
MSP1 locus (C). Genomic DNA of PfMSP1-19Pb8.7 clone (lanes 1–4 and 7) and wild-type P. berghei ANKA (lanes 5–6 and 8) were used as template; Test
primers are indicated by arrows. lane 1: amplification of gfp with the primers gfpF/gfpR; lane 2: verification of transfection using primers Tb/Tf; lanes 3
and 5: verification of the wild-type PbMSP-1 locus with the primers Tb5/T-Pb; lanes 4 and 6: verification of the predicted 59 integration into the
PbMSP-1 locus with the primers Tb5/Tf; lanes 7 and 8: verification of the predicted 39 integration into the PbMSP-1 locus with the primers 39veF/
39veR; M: base pair ladder (D). Probe PbM for Southern analysis was shown as black bar. The expected sizes of fragments resulting from digestion
with HincII are shown. S (SacI), B (BamHI), A (ApaI), K (KpnI) and H2(HincII).
doi:10.1371/journal.pone.0006894.g001
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stages
Blood samples were collected from the tails of mice infected with
the transgenic clones. Thin smears was prepared on the slides and
air-dried completely at room temperature. We did not take any
fixation procedure to the blood smears before fluorescence
detection. GFP fluorescence in the different blood stages was
visualized and recorded using the GFP filter settings of a Leica
TCSSP2 laser scanning confocal microscope.
The GFP fluorescence intensity of transgenic parasites in blood
stages was analyzed by flow cytometry using a FACSCalibur
(Becton Dickinson, CA, USA). Excitation of cells was performed
with an argon ion laser at a wavelength of 488 nm and the
emission of the green fluorescence was detected using a band pass
filter of 530/30 nm. To determine the consistency between the
parasitemia (the percentage of infected erythrocytes) automated
counted by flow cytometry and the parasitemia manually counted
in Giemsa stained blood films, 5 naı ¨ve female BALB/c mice were
intraperitoneally inoculated 2610
5 transgenic P. berghei parasites.
Tail blood was collected from each mouse (10 ml per sample) in
heparin (1 U/ul) daily, diluted in 2–3 ml of PBS, and then
analyzed using the FACSCalibur. In these samples, erythrocytes
were selected on size for analysis by gating on forward/side-light
scatter. By gating the uninfected erythrocytes and the GFP-
positive infected erythrocytes, parasitemia was determined by flow
cytometry in the infected mice with parasitemia levels between 0.1
and 12%. Giemsa-stained blood films were also prepared and
counted daily. The data were analyzed with SPSS15.0.
Western blot analysis
The P. falciparum and P. berghei schizont- or merozoite-infected
erythrocytes were harvested, washed three times with phosphate
buffered saline (PBS, pH 7.4) and pelleted by centrifugation (1,500
rpm for 8 min at room temperature). The pellets were lysed in an
equal volume of 0.15% saponin in PBS for 30 min at 37uC and
the released parasites were pelleted, washed 3 times with ice-cold
PBS (10,000 rpm for 10 min at 4uC). The parasite pellet was
resuspended in 1 mM phenylmethylsulfonyl fluoride (PMSF) and
100 mM EDTA, repeatedly freezed and thawed using liquid
nitrogen, incubated in Solution Buffer (50 mM Tris-HCl, 10 mM
EDTA, 1 mM PMSF, 1% Triton X-100) on ice for 1 h and then
centrifuged (10,000 rpm for10 min at 4uC) to remove insoluble
materials. Lysate supernatants were separated using nonreducing
8% and 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gels and transferred onto nitrocellu-
lose (NC) membranes. The membranes were blocked with 3%
non-fat dry milk/PBS, pH 7.4, and probed at 37uC for 1 h with
either affinity-purified anti-PfMSP1-19 rabbit polyclonal antibod-
ies [14] or anti-PbCP-2.9 (recombinant PbCP-2.9 also contains the
PbMSP1-19 antigen) mouse sera [31], both diluted 1:200 in 3%
non-fat dry milk/PBS, pH 7.4. Alkaline phosphatase-conjugated
goat anti-rabbit or goat anti-mouse secondary antibodies were
diluted 1:500 in 3% non-fat dry milk/PBS and added to the
membranes at 37uC for 1 h. At every step, the membranes were
washed three times with PBS containing 0.05% Tween 20,
pH 7.4. Bands were visualized using NBT (Nitro-Blue Tetrazoli-
um Chloride) and BCIP (5-Bromo-4-Chloro-39-Indolyphosphate
p-Toluidine Salt) as chromogenic substrates.
Growth rates of Transgenic P. berghei parasites
To compare growth rates, two groups of female BALB/c mice,
6–8 weeks of age (5 mice/group), were injected i.p. with 10
4
transgenic or wild-type P. berghei. Parasitemia was assessed daily in
Giemsa-stained thin smears prepared from tail blood of each
mouse. Parasitized erythrocytes were counted and the data were
expressed as the mean6SD of observations and statistical
differences were analyzed using the Mann-Whitney test.
Immunization with PfCP-2.9 and IgG purification
New Zealand White rabbits (n=3) were subcutaneously (s.c.)
immunized with 100 mg of PfCP-2.9 antigen emulsified with
Montanide ISA 720 adjuvant (Seppic Inc., Paris, France) while
control rabbits (n=3) received only PBS emulsified with
Montanide ISA 720. All rabbits received three immunizations at
2-week intervals with the same dose of antigen and adjuvant.
Bleeding was carried out on days 0 (pre-immune), 21 and 42, and
the sera were used for ELISA analysis and for IgG purification.
Total IgG was purified from rabbit sera using protein G
columns (Pierce Inc., Rockford, IL, USA). Briefly, rabbit sera was
diluted at least 1:2 with Binding Buffer (BB) (20 mM Tris-HCl,
pH 7.4) and loaded onto a protein G-Sepharose column. The
column was washed with 10-column volumes of BB, and the
bound IgG was eluted with 0.2 M glycine-HCl (pH 2.5). The pH
was immediately adjusted to 7–8 with 1 M Tris-HCl (pH 9.0).
The eluted fractions were dialyzed against RPMI 1640 (Invitro-
gen, Carlsbad, CA, USA) and concentrated with centrifugal filter
devices (Millipore, Billerica, MA USA) to a concentration above
20 mg/ml. Purified IgG was sterilized by filtration through a 0.22-
mm filter (Millipore). The integrity and purity of the antibodies was
verified on SDS-PAGE gels.
Passive transfer of IgG and parasite challenge
To test the protective efficacy of rabbit antibodies generated
against PfCP-2.9, purified IgG was passively transferred intrave-
nously (i.v.) into two groups of BALB/c mice (6–8 weeks old; 4
mice/group) given either 0.5 or 1.0 mg per dose at three times (on
days 21, 0 and +1 with respect to the parasite challenge). Thus,
the total doses of purified IgG for individual mouse were 1.5 and
3.0 mg, respectively. Control mice received purified IgG at the
same doses from adjuvant-only immunized rabbits. Transgenic P.
berghei were used for the parasite challenge. Parasitized erythro-
cytes (500/mouse) were injected i.v. 1 h after the IgG adminis-
tration on day 0. A similar set of four groups of mice that were
immunized in the same way was challenged with wild-type P.
berghei. Parasitemia was assessed daily in Giemsa-stained blood
smears prepared from each mouse. The time of death was
observed for all groups, and experiments were carried out twice.
Results
Construction of the transfection vector
Since integration into Plasmodium spp. genomes usually occurs via
homologous recombination, the two endogenous P. berghei
fragments, msp-1 (1.4 kb) and the 39UTR of PbMSP1 (0.5 kb),
were amplified from genomic DNA of P. berghei ANKA strain as
targeting sequences. The 39UTR of PbMSP-1 was cloned into the
KpnI/ApaI restriction sites upstream of the DHFR-TS/GFPmut2
fusion gene in the PyrFlu plasmid while the 1.4 kb P. berghei msp-1
fragment was fused in frame with the 0.33 kb msp1-19 region of P.
falciparum and ligated to the PfHSP86 39UTR at the 39 end of
PbfMSP-1 as a termination sequence. The PbfMSP-1/HSP86 39
fragment was cloned into the SacI/BamHI restriction sites
downstream of the DHFR-TS/GFPmut2 fusion gene, creating
the PyrFlu/PbfMSP-1/PbM39 vector. The complete sequences of
all the amplified fragments were verified by sequencing, and the
transfection vector was confirmed by PCR and enzyme digestion.
After linearization at the KpnI/SacI restriction sites, the vector
Transgenic Pb Parasite
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crossover event.
Genotype analysis of post-transfection parasites
The linear form of the transfection vector was introduced into
the blood stages of P. berghei by electroporation, and parasites were
selected using pyrimethamine. When green fluorescence was
observed in pyrimethamine-resistant parasites, cloning was
performed by limiting dilution. Genomic DNA of each clone
was extracted, and the correct integration was firstly verified by
PCR using the test primers. Since the vector could integrate into
the MSP1 gene locus of P. berghei, the PfMSP1-19 fragment
derived from P. falciparum replaced the corresponding endogenous
sequence of P. berghei. The 0.7 kb gfp fragment and 1.1 kb
fragment of the PbfMSP-1 fusion gene were amplified by the gfpF/
gfpR and Tb/Tf primers, respectively, to verify the presence of the
transfection vector in the parasite genome. The 1.8 kb fragment
amplified by the Tb5/Tf primers demonstrated the correct 59
integration into the msp1 gene locus of P. berghei, and the
amplification of the1.8 kb fragment was done using the Tb5/T-
Pb primers as controls for detecting the wild-type P. berghei msp1
gene. The 39 integration fidelity was confirmed by PCR
amplification of the 0.86 kb fragment using the primer pair
39veF/39veR.
During the first cloning phase eight (i.e. 1, 2, 7, 8, 10, 14, 15 and
19) of the pyrimethamine-resistant lines showed green fluores-
cence, but PCR amplification of these eight lines using the Tb5/Tf
and Tb5/T-Pb primers resulted in 1.8 kb bands, suggesting that a
mixed population containing wild-type and transgenic parasites
was present. We chose parasite line 8 as the initial population for
the second cloning, and obtained 4 clones (defined as 8.1, 8.4, 8.7
and 8.11) that had the correct vector integration as confirmed by
PCR analysis (figure 1D).
The parasite clone 8.7 (termed PfMSP1-19Pb8.7) was selected
for further Southern analysis and ‘passage stability’ assays. The
duration of the developmental asexual blood-stage of P. berghei
ANKA is 21 h. The parasite clone was allowed to proliferate in
vivo without drug pressure for 35 days and collected at weekly
intervals. Two PCR amplifications were performed. The 1.8-kb
integrated MSP1 locus was amplified using the Tb5/Tf primers
from all of the templates of transgenic parasites collected at the
different times whereas a 1.8-kb fragment was amplified only from
wild-type parasites using the Tb5/T-Pb primers (figures 2A). The
same quantity (10 mg) of genomic DNA of wild type and
transgenic P. berghei parasites was also digested with HincII
restriction enzyme and hybridized to probe PbM, which is specific
to the DNA sequences immediately upstream of P. berghei MSP1-
19. Digestion of the genomic DNA with this restriction enzyme
should generate a 12-kb fragment for the wild type P. berghei but a
4.6-kb fragment for the transgenic parasite that hybridized to this
probe. As shown in figure 2B, the bands corresponding to the wild-
type and transgenic P. berghei (i.e. 12 kb and 4.6 kb, respectively)
were detected by Southern blotting. Moreover, the signal
produced by the hybridization of the gene in the wild-type P.
berghei is similar to that of the transgenic parasite, and also the
signals are similar among the samples of the transgenic parasite
collected from various time points during the successive passage.
Green fluorescent detection and flow cytometry analysis
of transgenic parasites in blood stages
Blood was collected from the mice infected with transgenic
clone 8.7 (PfMSP1-19Pb8.7), and cells were examined by
fluorescence microscopy. Transgenic P. berghei in all erythrocyte
stages displayed clear fluorescent signals (figures 3A and B).
To determine whether all of the transgenic parasites of the
blood stages showed green fluorescence and could be readily
differentiated from other blood cells using flow cytometry, blood
samples were collected daily from PfMSP1-19Pb8.7-infected mice.
For each sample, 10
6 erythrocytes were analyzed for parasitemia
using FACScalibur and Cell Quest software (figure 3C). Simul-
taneously, the parasitemia of each sample was also determined on
Gimesa-stained smears. In these experiments, we observed a good
agreement between the counting of infected cells by flow
cytometry and manual counting of Giemsa-stained blood smears.
A strong correlation was found using Pearson’s correlation analysis
(n=20, R
2=0.981, P,0.001). The linear relationship in the
parasitemia from the two methods is shown in figure 3D.
Phenotypic analysis of transgenic malaria parasites
To determine whether the transgenic P. berghei clones expressed
heterologous MSP1-19 domains from P. falciparum, Western blot
analysis was performed on late-stage parasite extracts from P.
falciparum FCC1/HN, wild-type P. berghei ANKA and the
transgenic PfMSP1-19Pb8.7 clone. Purified rabbit antibodies to
Figure 2. PCR and Southern analysis of the stability of the
integrated locus in PfMSP1-19Pb8.7 clones. Genomic DNA was
extracted from transgenic parasites at various times with wild type
parasites as control. The primer pair of Tb5/Tf (upper line) was used to
detect the integrated fragment in the transgenic parasite, while the
primer pair of Tb5/T-Pb (lower line) was used to amplify the native
sequence of PbMSP1 in the wild-type parasites used as controls (A). Ten
micrograms of genomic DNA of wild type and transgenic P. berghei
parasites collected at different times was digested with HincII and
hybridized to probe PbM while the HincII-digested transfection plasmid
served as positive control (B). M: base pair ladder; lane 1: the genomic
DNA of wild type parasites; lanes 2–7: the genomic DNA of PfMSP1-
19Pb8.7 clone that was extracted at various times (days 0,7,14,21,28 and
35); lane 8: the DNA of transfection plasmid digested by HincII.
doi:10.1371/journal.pone.0006894.g002
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but also the 42-kDa and full-length bands in P. falciparum FCC1/
HN and PfMSP1-19Pb8.7, but did not interact with the
corresponding molecules in the wild-type P. berghei ANKA
(figure 4A). In contrast, the anti-PbCP-2.9 mouse sera only
recognized the 19-kDa and 42-kDa bands in the wild-type P.
berghei ANKA, but not in either P. falciparum FCC1/HN or
PfMSP1-19Pb8.7 (figure 4B). These results demonstrated that
PbfMSP-1 was expressed in transgenic parasites that were
generated by replacing the corresponding domain in P. berghei by
the PfMSP1-19.
The growth rates of transgenic clones were also examined and
compared to wild-type P. berghei parasite. Parasitemia was observed
in both mouse groups over a similar time frame and showed no
statistical differences (figure 5).
The efficacy of passive transfer of the anti-PfCP-2.9
antibodies
A group of 3 rabbits was immunized with PfCP-2.9 emulsified
in ISA720 adjuvant. After three immunizations, the reciprocal
antibody titers for each immunized rabbit were 3,200,000,
1,200,000 and 850,000, respectively, as measured by ELISA.
We chose the rabbit serum with the highest antibody titer to purify
the total IgG that was used for passive transfer.
To assess the protective efficacy of the anti-PfCP-2.9 antibodies,
total IgG from PfCP-2.9-immmunized and adjuvant-immunized
rabbits was passively transferred to BALB/c mice. The mice in
groups I and III were intravenously given IgG from adjuvant-only
treated animals (total doses of 1.5 and 3.0 mg, respectively) as
negative controls while the mice in groups II and IV received anti-
PfCP-2.9 IgG (total doses of 1.5 and 3.0 mg, respectively). Mice
from all groups were challenged with transgenic P. berghei. Mice in
the control group showed a continuous increase in parasitemia
and died by day 21. Conversely, mice passively transferred with
anti-PfCP-2.9 IgG survived, and no parasites were detected in the
blood up to 25 days following the lethal challenge (figure 6A). To
eliminate the possibility of non-specific protection or anti-PfCP-2.9
IgG cross-reactivity with P. berghei MSP1-19, four additional
groups of mice (groups VI-VIII) were immunized in a similar
fashion but challenged with wild-type P. berghei. All of the mice in
these groups developed an infection and died by day 23 (figure 6B).
These results suggested that antibodies to the PfCP-2.9 were
protective only against the transgenic P. berghei parasites that
contain the isoform of Pf MSP1-19.
Discussion
Transfection and gene targeting of Plasmodium parasites can
subtly disrupt, modify or replace genes, providing important
genetic tools to better understand gene function of malaria
parasites and their associated biological processes. To date,
transfection systems have been successful in some Plasmodium
species including the human, primate and rodent malaria parasites
[32–35]. The fact that an MSP1 deletion was lethal indicated that
this protein was essential for development of malaria parasites.
However, allelic replacement of the MSP1-19 across distantly-
related Plasmodium species has been successful [24,36,37], demon-
strating that the function of the MSP1-19 fragment was fully
conserved in vivo across species. The transgenic parasite lines have
Figure 3. GFP expression and flow cytometry analysis of
PfMSP1-19Pb8.7 clone in blood-stages. The same fields were
photographed using bright (left panel) and fluorescence microscopy
(right panel). Mature schizont stage (A). Early schizont stage (B). Flow
cytometry analysis of blood cells obtained from infected mice with
asynchronous infections. Per sample, 10
6 erythrocytes were analyzed.
Dot plots of blood cells were obtained from uninfected (upper line) and
PfMSP1-19Pb8.7-infected (lower line) mice. For counting the number of
infected cells the erythrocyte population was selected by size (forward-
scatter (FSC) and side-scatter (SSC)) as shown in the left panel. The
center panel shows the relative GFP-fluorescence intensity of cells in
the R1 region. Fluorescent erythrocytes were selected from region M2.
The right panel shows the dot plot of fluorescence intensity versus the
size of cells in R1. Fluorescent erythrocytes were selected in R3, non-
fluorescent in R2 (C). Correlation between the parasitemia counted by
flow cytometry and the parasitemia counted manually in Giemsa
stained blood films (D).
doi:10.1371/journal.pone.0006894.g003
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the in vivo evaluation of the inhibition function of specific
antibodies [21,22]. To evaluate the function of antibodies to the
PfCP-2.9 that contains the MSP1-19, we used gene targeting in
the P. berghei ANKA strain to construct a genetically modified
murine parasite in which the MSP1-19 of P. berghei was replaced by
the corresponding domain of P. falciparum. The resulting transgenic
parasites were demonstrated to express the Pb/Pf MSP-1 chimeric
protein. The growth characteristics of the transgenic parasites
were similar to that of the wild type P. berghei parasites throughout
the blood stages.
The green fluorescent protein (GFP) is a reporter protein that
has been widely used because it can easily be measured in living
organisms by fluorescence microscopy and flow cytometry.
Therefore, the transgenic parasites were constructed to express
GFP protein in addition to the PfMSP1-19. We found that the
GFP-expressing transgenic parasites in all blood stages could be
observed under a fluorescence microscope and that the parasit-
emia in the infected mice could be readily counted by flow
cytometry. The advantages of the simultaneous expression of the
Pb/Pf MSP-1 chimeric protein and GFP protein could be easy
detection of transgenic parasites during the blood stage and the
automated counting of parasitemia, which can potentially be used
for determination of in vivo vaccine efficacy and other biological
studies of malaria parasites related to MSP-1. In addition, with the
transgenic parasites, strain-specific protection can be analyzed in
mice against a challenge of mixed wild-type P. berghei and
transgenic parasites. Although other studies have generated
transgenic parasites that express either PfMSP1-19 or GFP
protein, the simultaneous expression of the PfMSP1-19 and GFP
should be superior to the expression of the molecules separately.
To create the transgenic P. berghei parasites, a pPyrFlu plasmid
that can express a pyrimethamine resistant gene and a GFP gene
as a DHFR-TS/GFP fusion protein was used [28]. Under the
control of the P. berghei DHFR-TS 59UTR, the fusion protein
could be constitutively expressed during the asexual RBC phase.
Since pyrimethamine selection frequently yields a proportion of
spontaneously resistant mutants that cannot be eliminated even
with higher drug doses and longer selection times, the selected P.
berghei parasite population actually contained both wild-type and
Figure 4. Western blot analysis of the PfMSP1-19 expression in PfMSP1-19Pb8.7 clone. Proteins extracted from enriched schizont
preparations of parental P. berghei ANKA, transgenic PfMSP1-19Pb8.7 clone and P. falciparum FCC1/HN, respectively, were probed with either anti-
PfMSP1-19 rabbit sera (A) or with anti-PbCP-2.9 mouse sera (B).
doi:10.1371/journal.pone.0006894.g004
Figure 5. Comparison of parasitemia between the transgenic
PfMSP1-19Pb8.7 parasite and its parental P. berghei. Two groups
of mice (5 mice/group) were infected with 10
4 erythrocytes harboring
either wild-type P. berghei ANKA or PfMSP1-19Pb8.7 clone. The
parasitemia was assessed daily using Giemsa-stained thin smears.
doi:10.1371/journal.pone.0006894.g005
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PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e6894Figure 6. Parasitemia profiles of the mice in the passive transfer experiment. Groups of mice were injected with a total amount of 1.5 mg
IgG (groups I and II) and 3.0 mg IgG (groups III and IV). (A): the mice in groups I and III were given IgG from adjuvant-only immunized rabbits, while
mice in groups II and IV received IgG purified from rabbits immunized with PfCP-2.9 antigen. All mice were challenged with PfMSP1-19Pb8.7




PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6894transgenic parasites. To identify the transgenic parasite clones, the
pyrimethamine-resistant parasites underwent two rounds of
cloning using the limiting dilution method. The parasite clones
were firstly verified by PCR analysis using five primer sets to
determine whether the integration and replacement occurred
correctly. As a result, only four resistant clones showed the desired
integration that was further confirmed by Southern blot analysis.
The stability of the integrated MSP-1 locus was also shown by
Southern analysis during 35 days of successive passages,
demonstrating that no reversion to the wild type had occurred.
To determine the phenotype of the transgenic P. berghei parasites,
one of the identified clones was chosen for analysis. The results of
Western blot analysis confirmed that only P. falciparum MSP1-19
was expressed in transgenic murine parasites, while the expression
of the endogenous PbMSP1-19 gene was not detected. A
comparison of amino acid sequence of PfMSP1-19 with that of
PbMSP1-19 indicates only 35% sequence identity and the lack of
one disulfide bond in the first EGF domain in P. berghei. However,
the detection of the full-length and processed forms of chimeric
PbfMSP-1 protein indicates that the proteolytic processing occurs
correctly in the transgenic P. berghei parasite and releases the
heterogenous PfMSP1-19. In addition, the growth rate of
transgenic P. berghei showed no statistical differences compared to
that of the wild-type. Our results demonstrated that the
replacement of the MSP1-19 region and the expression of
DHFR-TS/GFP fusion protein were not deleterious to the
transgenic P. berghei parasites. These results were consistent with
previous findings for functional conservation of MSP1-19 domain
between human and murine Plasmodium species [24,36,37].
Humans are the natural host for P. falciparum, and the lack of
animal models for infections with this Plasmodium species makes the
discovery of vaccine candidates challenging. The evaluation of the
immune protective efficacies of malaria vaccines often involves the
use of robust and reliable assays. The in vitro Growth Inhibition
Assay is a rapid and inexpensive way of evaluating protective
immunity and provides valuable information on the function of
immune sera, but an accurate and full assessment of inhibitory
activity with this in vitro method is difficult. Moreover, at present
there is no demonstrable in vitro assay that directly correlates
protective immune efficacy. In this study, we generated a
transgenic P. berghei that expresses both P. falciparum MSP1-19
and GFP protein simultaneously, providing a model to further test
the protective efficacy of the PfCP-2.9 vaccine. We found that only
mice given the purified IgG from PfCP-2.9-vaccinated rabbits
survived a lethal challenge of transgenic murine parasites,
indicating that PfCP-2.9 elicited the production of inhibitory
anti-MSP1-19 antibodies that provided protection against the
parasite in vivo at a low dose parasite challenge (500 infected RBC
per mouse). The fact that all of the mice that were also given IgG
from PfCP-2.9-vaccinated rabbits developed an infection of wild-
type P. berghei eliminated the possible cross-species protection of
antibodies elicited by PfCP-2.9. Taken together, using gene
targeting we generated a P. berghei line that expresses PfMSP1-19
and the GFP reporter gene simultaneously. In this transgenic line,
MSP1-19 derived from P. falciparum complemented the in vivo
function of its own MSP1-19 domain, at least in the erythrocytic
stage, although P. berghei MSP1-19 lacks one disulfide bond in the
first EGF domain and shares only 35% amino acid identity to P.
falciparum MSP1-19. Transgenic parasites are similar to the wild-
type parasites in proliferation and invasion of erythrocytes. The
availability of transgenic P. berghei that expresses P. falciparum
MSP1-19 and GFP protein provides a murine model to evaluate
protective efficacy in vivo of anti-MSP1-19 antibodies, including
those elicited by the PfCP-2.9 malaria vaccine in human
volunteers.
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